On Monday, Shares of Calithera Biosciences Inc (NASDAQ:CALA), dropped -20.66% to $7.95. The firm opened its current trade at $10.14. The total volume traded for the day is 1.23M shares, as compared to its average daily volume of 337,311.00 shares. The stock is floating in a range of $6.72 - $10.15. The stocks hold the market capitalization of $180.70M.
Calithera Biosciences, Inc. (CALA), declare new clinical data from the solid tumor expansion cohorts of its lead anti-cancer therapeutic candidate, CB-839, at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets in Boston, Massachusetts. CB-839 is a potent, selective, orally bioavailable glutaminase inhibitor in phase I clinical trials. The data support earlier findings of the clinical activity, tolerability and unique mechanism of action of CB-839 in patients with solid tumors, in addition to show one partial response according to RECIST criteria.
“We are very encouraged by these findings in that they reinforce the published safety and efficacy profile of CB-839. We believe that this first partial response in solid tumors points to the potential of our novel agent’s efficacy in renal cell carcinoma, and we look forward to sharing data as our single agent and combination studies mature,” said Susan Molineaux, PhD, President and Chief Executive Officer of Calithera. “We are presently expanding enrollment of CB-839 as a monotherapy in renal cell carcinoma patients, in addition to dosing CB-839 in combination with everolimus.”
Catalina Lighting, Inc. designs, manufactures, imports, warehouses, and distributes electric lamps and lighting fixtures. The company was incorporated in 1974 and is based in Miami, Florida.
Shares of Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR), declined -20.66% to $12.98. The firm opened its current trade at $16.24. The year-to-date (YTD) performance of AEGR stock reflects that it is -38.06% below last year. During the past month, the stock decline -11.23%, bringing three-month performance to -28.66% and six-month performance to -37.79%.
The mean estimate for the short term price target for Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR), stands at $23.60 according to 5 Analysts. The higher price target estimate for the stock has been calculated at $38.00 while the lower price target estimate is at $9.00.
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States. The companys products comprise JUXTAPID (lomitapide) capsules, an adjunct to a low-fat diet and other lipid-lowering treatments, counting low-density lipoprotein, low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol in adult patients with homozygous familial hypercholesterolemia (HoFH); and LOJUXTA (lomitapide) hard capsule used as a treatment for HoFH in adults. Its products also comprise MYALEPT (metreleptin), a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or attained generalized lipodystrophy.
Shares of Mallinckrodt PLC (NYSE:MNK) dipped -16.44% to $58.40. The firm opened its current trade at $70.00. The total volume traded for the day is 6.19M shares, as compared to its average daily volume of 3.47M shares. The stock is floating in a range of $52.01 - $70.21. The stocks hold the market capitalization of $7.37B.
Mallinckrodt Plc shares plummeted after the drugmaker was mentioned on Twitter by Citron Research, the stock-commentary site whose scrutiny assisted lead to a rout of Valeant Pharmaceuticals International Inc.’s stock, according to Bloomberg
Mallinckrodt said last month that unlike Valeant, it doesn’t own or have a stake in specialty pharmacies. The company does have contractual arrangements with specialty pharmacies for the distribution of H.P. Acthar Gel, a treatment for lupus and other disorders of the immune system that the drugmaker gained when it agreed to buy Questcor Pharmaceuticals Inc. last year for about $5.6 billion.
The company said at the time that it has worked with doctors and hospitals to show the benefits of Ofirmev as an alternative to opioid painkillers. The company said an increasing number of hospitals are seeing the value of the drug, which is “driving positive momentum in Ofirmev volume.” Bloomberg Report
Mallinckrodt Public Limited Company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
